Zelira Therapeutics Ltd
ZLD
Company Profile
Business description
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.
Contact
101 St George’s Terrace
Level 3
PerthWA6000
AUST: +61 865580886
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
8
Stocks News & Analysis
stocks
ASX small caps offering great value right now
Considering investing in small caps? See our top ASX picks.
stocks
Avoid this overpriced ASX healthcare company
The shares are trading at a 47% premium to our fair value.
stocks
Ask the analyst: Why have Healius shares struggled so much?
Shares in Australia's second biggest pathology operator have floundered in recent years. Shane Ponraj thinks better days could be ahead.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,699.10 | 0.90 | -0.01% |
| CAC 40 | 7,235.11 | 55.86 | 0.78% |
| DAX 40 | 19,626.45 | 200.72 | 1.03% |
| Dow JONES (US) | 44,910.65 | 188.59 | 0.42% |
| FTSE 100 | 8,287.30 | 6.08 | 0.07% |
| HKSE | 19,423.61 | 56.65 | 0.29% |
| NASDAQ | 19,218.17 | 157.69 | 0.83% |
| Nikkei 225 | 38,208.03 | 141.03 | -0.37% |
| NZX 50 Index | 13,066.92 | 13.36 | 0.10% |
| S&P 500 | 6,032.38 | 33.64 | 0.56% |
| S&P/ASX 200 | 8,436.20 | 8.10 | -0.10% |
| SSE Composite Index | 3,326.46 | 30.76 | 0.93% |